FEB 24, 2016
Precision Medicine 2016
29 117 33297

LabRoots' exciting new free virtual event – Precision Medicine 2016 - was a success! This event is now On Demand. Watch a remarkable line-up of industry, government and academic experts, including architects of the Precision Medicine Initiative, in recorded webcasts any time. These presentations showcase the latest advances in diagnostics, therapeutics and individualized medicine that are transforming the future of personalized healthcare.

Learn more about this exciting event by watching this video.

Imagine receiving a full diagnosis from a simple blood test, or the ability to tailor the perfect treatment to your individual genetic makeup, taking into account your specific susceptibilities to side effects. What if we could apply a patient’s genetic information to gain insights into the genetic variations of diseases and expedite drug development, to create more precise therapies? This is the goal of Precision Medicine.

Precision Medicine Initiative ® (PMI) is a Presidential initiative, calling for initial funding of $215 million to support the creation of a national research cohort of 1 million or more U.S. volunteers (the PMI Cohort Program; $130 million), new efforts in cancer drug development ($70 million), advances in FDA regulatory structures ($10 million), and development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems through the ONC ($5 million). The PMI builds on stunning advances in next-generation sequencing, genome biology, cancer diagnostics, biomarkers, targeted drug development, adaptive clinical trials, and digital health.

Since the completion of the Human Genome Project, extraordinary progress has been made in understanding the reach and impacts of human genetic variation. Advances in sequencing, genomic analysis, biomarker detection, coupled with new insights into rational drug design and repurposing, have given doctors more powerful and selective tools to help treat disease by tailoring medicines to an individual's genetic profile.  Given that individuals’ health and disease are woven into a complex web of factors, the PMI Research Cohort will assemble not only genetic, but also environmental, behavioral, and clinical data so that researchers may  understand the full range of factors that inform health and disease as they search for precision approaches to health maintenance, disease prevention, and therapies.

We are proud to include C&EN as our partner in this virtual event. 

Topics include:

  • Next-Gen Sequencing in the clinic
  • Therapies for Rare diseases
  • Biobanking
  • Personalized cancer therapeutics
  • Rational Drug Design
  • Cancer diagnostics and liquid biopsies
  • Biomarkers
  • Alternative drug therapies
  • Electronic Health Records
  • Data Storage and Analytics

 “Doctors have always recognized that every patient is unique, and doctors have always tried to tailor their treatments as best they can to individuals. You can match a blood transfusion to a blood type — that was an important discovery. What if matching a cancer cure to our genetic code was just as easy, just as standard? What if figuring out the right dose of medicine was as simple as taking our temperature?”
                                                                                    --- President Obama, January 30, 2015


Continuing Education
By participating in this virtual event and watching webcast presentations, you can earn Free Continuing Education (CE) and/or Continuing Medical Education (CME) credits. To earn educational credits, you must view an entire presentation. Following the presentation you must click on the educational credit link provided for that particular speaker and follow the required process. Once you have completed the process, you will receive a certificate for the educational credit.

Use #LRprecisionmed to follow the conversation
 


Speakers:
  • Deputy Director for Science, Outreach and Policy, NIH
  • Jean C. and James W. Crystal Professor of Genomics, Chairman and Professor, Department of Genetics and Genomic Sciences, Director, Icahn Institute for Genomics and Multiscale Biology, Icahn S
  • Associate Professor of Medicine (Cardiovascular), of Genetics and, by courtesy, of Pathology at the Stanford University Medical Center
  • Professor of Bioinformatics, Head of Department of Medical & Molecular Genetics, Director of Bioinformatics King's Health Partners, Faculty of Life Sciences & Medicine, King's College London
  • Professor, Computer Science and AI Lab, Director, MIT Computational Biology Group, Broad Institute of MIT and Harvard
  • Co-founder and executive vice president, GNS Healthcare
  • Senior Director and Global Development Lead, NGS, QIAGEN
  • Director of the Innovation Center for Biomedical Informatics (ICBI) and Associate Professor of Oncology, Georgetown University Medical Center
  • VP and Head of Personalised Healthcare and Biomarkers, AstraZeneca
  • Strategic Innovation Leader, Pharma Development, Roche Diagnostics
  • Research Professor Division of Chemical Systems & Synthetic Biology Department of Integrative Biomedical Sciences, University of Cape Town Faculty of Health Sciences
  • Senior Director, Scientific Engagement & Public Outreach, New York Genome Center
  • Global Product Manager, NGS, QIAGEN
  • Professor, Columbia University, Departments of Biological Sciences and Chemistry

Show Resources
Agenda
All times are Pacific Time
  • FEB 24, 2016 05:00 AM PST
    Speaker: Ruth March, PhD
  • FEB 24, 2016 06:00 AM PST
    Speaker: Raed Samara, PhD
  • FEB 24, 2016 06:00 AM PST
    Speaker: Tim Hubbard, PhD
  • FEB 24, 2016 07:00 AM PST
    Speaker: Thomas Metcalfe
  • FEB 24, 2016 07:00 AM PST
    Speaker: Euan Ashley, MRCP, DPhil
  • FEB 24, 2016 08:00 AM PST
    Speaker: Eric Schadt, PhD
  • FEB 24, 2016 09:00 AM PST
    Speaker: Kathy Hudson, PhD
  • FEB 24, 2016 10:00 AM PST
    Speaker: Iya Khalil, PhD
  • FEB 24, 2016 11:00 AM PST
    Speaker: Brent Stockwell, PhD
  • FEB 24, 2016 12:00 PM PST
    Speaker: Subha Madhavan, PhD
  • FEB 24, 2016 01:00 PM PST
    Speaker: John Leamon, PhD
  • FEB 24, 2016 01:00 PM PST
    Speaker: Manolis Kellis, PhD
  • FEB 24, 2016 02:00 PM PST
    Speaker: Nathaniel Pearson, PhD
  • FEB 24, 2016 03:00 PM PST
    Speaker: Musa Mhlanga, PhD
  • Rational Drug Design
  • FEB 24, 2016 05:00 AM PST
    Speaker: Ruth March, PhD
  • Personalized Cancer Therapeutics, Diagnostics and Liquid Biopsies
  • FEB 24, 2016 06:00 AM PST
    Speaker: Raed Samara, PhD
  • FEB 24, 2016 07:00 AM PST
    Speaker: Thomas Metcalfe
  • FEB 24, 2016 10:00 AM PST
    Speaker: Iya Khalil, PhD
  • FEB 24, 2016 11:00 AM PST
    Speaker: Brent Stockwell, PhD
  • FEB 24, 2016 12:00 PM PST
    Speaker: Subha Madhavan, PhD
  • FEB 24, 2016 01:00 PM PST
    Speaker: John Leamon, PhD
  • Genomic Medicine
  • FEB 24, 2016 06:00 AM PST
    Speaker: Tim Hubbard, PhD
  • FEB 24, 2016 07:00 AM PST
    Speaker: Euan Ashley, MRCP, DPhil
  • FEB 24, 2016 08:00 AM PST
    Speaker: Eric Schadt, PhD
  • FEB 24, 2016 01:00 PM PST
    Speaker: Manolis Kellis, PhD
  • FEB 24, 2016 02:00 PM PST
    Speaker: Nathaniel Pearson, PhD
  • Biobanking and Community Health
  • FEB 24, 2016 09:00 AM PST
    Speaker: Kathy Hudson, PhD
  • FEB 24, 2016 03:00 PM PST
    Speaker: Musa Mhlanga, PhD
Speakers

  • Kathy Hudson, PhD
    Deputy Director for Science, Outreach and Policy, NIH
    Biography
      Kathy L. Hudson, Ph.D., is the Deputy Director for Science, Outreach, and Policy at the National Institutes of Health (NIH). Dr. Hudson leads the science policy, legislation, communication, and outreach efforts of the NIH and serves as a senior advisor to the NIH director. She is responsible for creating major new strategic and scientific initiatives for NIH and is currently leading the planning and creation of the President's Precision Medicine Initiative Cohort Program. Dr. Hudson was a key architect of the National Center for Advancing Translational Sciences and the NIH BRAIN Initiative. She directs the agency's efforts to advance biomedical research through policy development, public and stakeholder communication and education, and innovative projects and partnerships. Dr. Hudson's professional experience includes serving as the NIH Chief of Staff; Acting Deputy Director of the National Center for Advancing Translational Sciences, NIH; the Assistant Director of the National Human Genome Research Institute, NIH; and the founder and Director of the Genetics and Public Policy Center at John Hopkins University. Also at Hopkins, Dr. Hudson was an Associate Professor in the Berman Institute of Bioethics, Institute of Genetic Medicine, and Department of Pediatrics. Dr. Hudson holds a Ph.D. in Molecular Biology from the University of California at Berkeley, an M.S. in Microbiology from the University of Chicago, and a B.A. in Biology from Carleton College.
    • Eric Schadt, PhD
      Jean C. and James W. Crystal Professor of Genomics, Chairman and Professor, Department of Genetics and Genomic Sciences, Director, Icahn Institute for Genomics and Multiscale Biology, Icahn S
      Biography
        Eric Schadt, PhD, is Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai. Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. He is known for calling for a shift in molecular biology toward a network-oriented view of living systems to complement the reductionist, single-gene approaches that currently dominate biology in order to more accurately model the complexity of biological systems. He has published more than 200 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer's disease. Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from University of California, Davis, and his Ph.D. in bio-mathematics from University of California, Los Angeles (requiring Ph.D. candidacy in molecular biology and mathematics).
      • Euan Ashley, MRCP, DPhil
        Associate Professor of Medicine (Cardiovascular), of Genetics and, by courtesy, of Pathology at the Stanford University Medical Center
        Biography
          Born and raised in Scotland, Euan Ashley graduated with 1st class Honors in Physiology and Medicine from the University of Glasgow. He completed medical residency and a PhD in molecular physiology at the University of Oxford before moving to Stanford University where he trained in cardiology and advanced heart failure, joining the faculty in 2006. His group is focused on precision medicine. In 2010, he led the team that carried out the first clinical interpretation of a human genome. The paper published in the Lancet was the focus of over 300 news stories, became one of the most cited articles in clinical medicine that year, and was featured in the Genome Exhibition at the Smithsonian in DC. The team extended the approach in 2011 to a family of four and now routinely applies genome sequencing to the diagnosis of patients at Stanford hospital where Dr Ashley directs the Clinical Genome Service and the Center for Inherited Cardiovascular Disease. In 2013, Dr Ashley was recognized by the White House Office of Science and Technology Policy for his contributions to Personalized Medicine. In 2014, Dr Ashley became co-chair of the steering committee of the NIH Undiagnosed Diseases Network. Dr Ashley is co-Principal Investigator of the MyHeartCounts study, launched in collaboration with Apple in 2015. Dr Ashley is a recipient of the National Innovation Award from the American Heart Association (AHA) and a National Institutes of Health (NIH) Director's New Innovator Award. He is a peer reviewer for the NIH and the AHA as well as multiple scientific and medical journals. He is Senior Associate Editor of Circulation Cardiovascular Genetics and a member of the Editorial board of Molecular Case Studies. He is co-founder of Personalis Inc, a genome scale genetic diagnostics company founded in 2012 operating now in more than 10 countries around the world. Father to three young Americans, in his ‘spare' time, he tries to understand American football, plays the saxophone, and conducts research on the health benefits of single malt Scotch whisky.
        • Tim Hubbard, PhD
          Professor of Bioinformatics, Head of Department of Medical & Molecular Genetics, Director of Bioinformatics King's Health Partners, Faculty of Life Sciences & Medicine, King's College London
          Biography
            Tim J. P. Hubbard is Professor of Bioinformatics, Head of Department of Medical and Molecular Genetics 
at King's College London and Director of Bioinformatics
 for King's Health Partners/King's College London. He is 
also Head of Genome Analysis at Genomics England,
 the company set up by the UK Department of Health to execute the 100,000 genomes project, which aims to mainstream the use of whole genome sequence analysis for treatment in the UK National Health Service (NHS). Tim graduated with a BA in Biochemistry 
from University of Cambridge in 1985 and a PhD in 
Protein Design from the Department of Crystallography,
 Birkbeck College, London, in 1988. In 1997 he joined
 the Wellcome Trust Sanger Institute where he was one of the organizers of the sequencing of the human genome. In 1999 he co-founded the Ensembl project to analysis, organise and provide access to the human genome and from 2007 led the GENCODE project to annotate the structure of all human genes. Tim's research interests are in bioinformatics, computational biology and genome informatics. He is also actively involved in efforts to improve data sharing in science and develop open access publishing resources. He is a member of the cross funding agency Expert Advisory Board on Data Access (EAGDA) and is chair of the Advisory Board of Europe PubMedCentral.
          • Manolis Kellis, PhD
            Professor, Computer Science and AI Lab, Director, MIT Computational Biology Group, Broad Institute of MIT and Harvard
            Biography
              Manolis Kellis is a Professor of Computer Science at MIT, where he directs the MIT Computational Biology Group (compbio.mit.edu). He has helped direct several large-scale genomics projects, including the NIH Roadmap Epigenomics project, the comparative analysis of 29 mammals, the Encyclopedia of DNA Elements (ENCODE) project, and the Genotype Tissue-Expression (GTEx) project. He received the US Presidential Early Career Award in Science and Engineering (PECASE), the NSF CAREER award, the Alfred P. Sloan Fellowship. He obtained his Ph.D. from MIT, where he received the Sprowls award for the best doctorate thesis in computer science. He lived in Greece and France before moving to the US.
            • Iya Khalil, PhD
              Co-founder and executive vice president, GNS Healthcare
              Biography
                Iya Khalil, co-founder and executive vice president of GNS, has promoted use of the Cambridge, MA-based company's technology in the biopharma industry. One of the inventors of the company's computational platform, her work has helped major players such as Biogen Idec and Johnson & Johnson to make computer-driven discoveries for their respective R&D programs. Biopharma companies' lack of biological understanding explains a great many miserable failures in drug development. GNS' approach, known as reverse engineering/forward simulation, is able to crunch billions of genomic, molecular and clinical data points and identify cause-and-effect relationships. Such insights help pinpoint predictive biomarkers for experimental drugs and new targets for therapies. Khalil has pushed personalized medicine toward reality for more than a decade. She and GNS CEO Colin Hill started the company more than 11 years back while Khalil was wrapping up her Ph.D. in theoretical physics at Cornell University, and she has been at the forefront of integrating computational biology into the drug development process.
              • John Leamon, PhD
                Senior Director and Global Development Lead, NGS, QIAGEN
                Biography
                  John obtained his Ph.D. in Physiology and Neurobiology from the University of Connecticut in 1999. His postdoctoral research was at Yale School of Medicine under Dr. Paul Lizardi. John has been active in the NGS field since its inception, directly involved in establishing both 454 and Ion Torrent sequencing systems, as well as supporting enrichment technologies such as RainDance and AmpliSeq. John is currently a Senior Director and Global Development Lead for NGS Technologies at Qiagen Corporation. He has published 25 papers, sits on several scientific advisory boards and is an inventor on numerous issued patents and patent applications
                • Subha Madhavan, PhD
                  Director of the Innovation Center for Biomedical Informatics (ICBI) and Associate Professor of Oncology, Georgetown University Medical Center
                  Biography
                    Dr. Subha Madhavan is Director of the Innovation Center for Biomedical Informatics (ICBI) at the Georgetown University Medical Center and Associate Professor of Oncology. She is a world-class leader in data science, clinical informatics and health IT who is responsible for several biomedical informatics efforts including the software development of Georgetown Database of Cancer (G-DOC) a resource for both researchers and clinicians to realize the goals of personalized medicine and co-directs Lombardi Cancer Center's Biostatistics and Bioinformatics shared resource. In her role as the CTSA biomedical informatics director, she has enabled access to over 2.5 million patient records from 10 MedStar Health hospitals to translational researchers. She was the PI on the Breast and Colon Cancer Family Registries data center that coordinates public health and epidemiology data across 12 sites in the US, Australia, and Canada. More recently, she has partnered with the FDA on the Center for Excellence in Regulatory Science program to develop evidence bases for pharmacogenomics and vaccine safety. She collaborated with the Inova translational medicine institute to help manage 1000's of patient genomes on the Amazon cloud to facilitate large-scale statistical analysis and genotype-phenotype association testing. She has contributed to novel information sciences findings in research articles published in journals such as Nature, Bioinformatics, Molecular and Cell Biology (MCB), AJPM, Frontiers in Oncology, Bioinformatics, Cancer Informatics, and Molecular Cancer Research (MCR). Dr. Madhavan has a Master's degree in Information Technology from University of Maryland and a Ph.D. in Molecular Biology and Biological Sciences from the Uniformed Services University for the Health Sciences through a highly ranked Indo-US Collaborative program.
                  • Ruth March, PhD
                    VP and Head of Personalised Healthcare and Biomarkers, AstraZeneca
                    Biography
                      Ruth March, VP and Head of Personalised Healthcare and Biomarkers, leads AstraZeneca's function of world class diagnostic and biomarker science experts, delivering companion diagnostic tests to target AZ drugs to the right patients across each therapy area and all phases of development. She has driven adoption of Personalised Healthcare approaches by 70% of AstraZeneca's pipeline, partnering with a strategic network of diagnostic companies to ensure delivery to global clinical trials and marketed products. Ruth spent ten years in immunology and genetics research at the Universities of London and Oxford. She has over 40 publications and patents in the field of pharmacogenomics and Personalised Healthcare and serves as an expert evaluator for the European Commission.
                    • Thomas Metcalfe
                      Strategic Innovation Leader, Pharma Development, Roche Diagnostics
                      Biography
                        Tom Metcalfe joined Pharma Development (PD) Strategic Innovation as a Strategic Innovation Leader in March 2015. The Strategic Innovation group has the task of enabling PD to meet the challenges of 2020 and beyond by building innovative new skills, capabilities, processes and organizations. Tom's particular focus is on Precision Medicine. Prior to this appointment Tom worked for a year leading part of Project TRINiTY, a project within the Roche Pharma Regulatory Community in Europe. He rejoined Roche from Oncotest GmbH where he was Managing Director and co-CEO. Oncotest is a preclinical CRO which assesses the preclinical efficacy of oncology molecules using well characterized Patient Derived Tumorgrafts. Before this Tom spent 18 years working for Roche in a variety of functions. He joined Roche's Diagnostics business in 1993. In 1998 he was appointed Global Head of Strategic Marketing of Roche Applied Sciences. In 2001 he moved to Roche Molecular Diagnostics as Head of BD and the Clinical Genomics business. In 2004 Tom joined Roche Pharma as Global Head of the Roche Biomarker Program and from 2007 onwards became Head of Roche's Personalised Healthcare Portfolio. In 2010 Tom joined the Translational Research Sciences group of Roche's Pharma Research and Exploratory Development organization, where he was responsible for external collaborations. Tom studied Biochemistry at King's College, London University in 1982 and gained an MBA from the Open University, UK in 1996. Tom also spent 18 months between 2009 and 2011 as chair of the European Biopharmaceutical Enterprises' Task Force on Personalised Medicines.
                      • Musa Mhlanga, PhD
                        Research Professor Division of Chemical Systems & Synthetic Biology Department of Integrative Biomedical Sciences, University of Cape Town Faculty of Health Sciences
                        Biography
                          Musa M. Mhlanga (USA citizen), American-born male cell biologist, holds a PhD in cell biology & molecular genetics from New York University School of Medicine (2003). He began his PhD at The Rockefeller University in the laboratory of David Ho where he worked on spectral genotyping of human alleles. He then went on to work on the development of in vitro and in vivo applications of molecular beacons for their use in visualizing RNA in living cells with Fred Russell Kramer and Sanjay Tyagi at New York University School of Medicine. Upon completion of his doctoral work he was awarded a U.S. National Science Foundation post-doctoral fellowship at the Institut Pasteur in Paris, France to work in the laboratory of nuclear cell biology. There he worked on RNA transport and single molecule visualization and tracking of RNA in living cells. In late 2008 he moved his lab to South Africa to join the Council of Scientific and Industrial Research as the Research Leader of the Synthetic Biology Emerging Research Area. He heads the Laboratory for Gene Expression & Biophysics and holds a joint appointment to the Institute of Molecular Medicine in Lisbon, Portugal. His laboratory works on gene regulation, host-pathogen interactions, single molecule imaging of gene expression and the development of cell-based visual high-throughput biology techniques for screening in basic and clinical biology.
                        • Nathaniel Pearson, PhD
                          Senior Director, Scientific Engagement & Public Outreach, New York Genome Center
                          Biography
                            Nathan Pearson is a Senior Director of Scientific Engagement & Public Outreach at NY Genome Center, where he and his colleagues build simple, engaging tools that compare one whole human genome to the next, in order to cast new light on human health and history. Fascinated by human genetic diversity since working as a young student in the laboratory of Luca Cavalli-Sforza (Stanford University), he traveled with Spencer Wells (now head of the Genographic Project) to collect DNA from people living throughout Eurasia, to reveal traces of ancient migrations recorded in their genomes. In doctoral work at the University of Chicago, he studied patterns of sequence variation on the great ape sex chromosomes, spotlighting how mutation, recombination, and natural selection have jointly made the X and Y ever more different from each other. Later, in post-doctoral work at the University of Michigan, he first delved into the emerging world of high-throughput sequencing, grasping its power to address important open questions in biology. Today, working with a talented team of scientists and programmers, he helps researchers and consumers sift through the billions of letters in each human genome, and understand which important spellings make each person unique.
                          • Raed Samara, PhD
                            Global Product Manager, NGS, QIAGEN
                            Biography
                              Raed Samara, PhD is a Global Product Manager for NGS technologies at QIAGEN, with a focus on pre-analytics and targeted enrichment. Prior to joining QIAGEN, he was a postdoctoral fellow at the National Cancer Institute conducting research in the field of cancer immunology with emphasis on identifying strategies to boost the efficacy of cancer vaccines. He received his Ph.D. degree from Georgetown University in tumor biology.
                            • Brent Stockwell, PhD
                              Professor, Columbia University, Departments of Biological Sciences and Chemistry
                              Biography
                                A decorated researcher, Stockwell is investigating mechanisms of cell death and exploring their application in the treatment of cancer and neurodegeneration. His investigations have not only identified drug candidates, they've inspired new methods of small molecule drug discovery. Stockwell is author of The Quest for the Cure: The Science and Stories Behind the Next Generation of Medicines.
                              Sponsored By

                              For information on becoming a sponsor or exhibitor, please click here.


                              Continuing Education (CME/CE/CEU) Credits

                              The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here


                              Committee

                              To download the Program Committee brochure here.


                              • Kevin Davies, PhD

                                Kevin Davies, Ph.D. is an author, editor and publisher with 25 years' experience in the world of scientific publishing. He is currently publisher of C&EN (Chemical & Engineering News), the weekly news and science magazine of the American Chemical Society, the largest scientific ...

                                See more See less
                              Help

                              General LabRoots Questions

                              For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                              Contact us

                              Virtual Events and Webinars

                              Supported Configurations

                              • Operating System Internet Explorer Firefox Chrome Safari
                                Vista IE8+ FF10+ Chrome15+
                                Windows 7 IE8+ FF10+ Chrome15+
                                Windows 8 IE10 FF10+ Chrome15+
                                Mac OS X   FF10+ Chrome15+ Safari5.1+
                              • Cookie settings: session cookies enabled
                              • Browser configuration must have JavaScript enabled
                              • Adobe Flash player 10.2 or later

                              To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                              Internet Connection

                              • A minimum of 100Kbps is recommended for audio-only events
                              • A minimum of 300Kbps is recommended for speaker on-video events

                              Computer Equipment

                              • Screen Resolution: Minimum 1024x768
                              • Video Card: 65,000 colors minimum
                              • Sound card and speakers (or headphones) for hearing webcast in full format
                              • Audio Card: 16-bit minimum
                              • RAM: 512MB of free RAM

                              Firewall Protocol

                              • HTTP on port 80 or HTTPS on port 443
                              • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                              • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                              Work-At-Home Attendees

                              • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                              For A Seamless Experience

                              When using a mobile device, FREE Mobile Apps are available:

                              - For viewing Webinars:

                              - For viewing Virtual Events

                              Attendee Guide

                              • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                              Virtual Event and Webinar Support:

                              Continuing Education (CME/CE) Support

                              Loading Comments...
                              Show Resources